Bayer Biological Products Bayer HealthCare - Boliogical Products Division
                SearchSitemap 
HomeAbout UsAbout HaemophiliaFor KidsResearch & DevelopmentPress Releases 
  Recombinant Factor VIII
Related Links
   Haemo-QoL Project
   Hemophilia Research Awards
   Living With Hemophilia
   More Haemophila Websites
Bayer Links
   Bayer Global
   Bayer HealthCare
   Bayer BP Global
   Bayer EU Sites
   General Conditions of Use
Privacy Statement
Imprint

© 2004 Bayer HealthCare, LLC

This website is intended for EU residents.

 

New Routes of Production

Printable Version

Using Gene and Biotechnology to Manufacture Factor VIII

Lack of functional Factor VIII is responsible for the disease Haemophilia A. In humans, Factor VIII is normally produced in the liver and transported into the bloodstream.

Until recently, Factor VIII for treatment of Haemophilia A was isolated from human blood. This carried the risk of potential transmission of infectious agents present in the donated blood.

Gene technology permits production of human Factor VIII of high quality in large amounts through the use of cultured cells. The procedure is safe and has now become routine.